Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks
Open on Zacks
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Wall Street analysts forecast that Gilead Sciences (GILD) will report quarterly earnings of $2.17 per share in its upcoming release, pointing to a year-over-year decline of 12.2%. It is anticipated that revenues will amount to $7.81 billion, exhibiting an increase of 0.6% compared to the year-ago quarter.

The consensus EPS estimate for the quarter has undergone a downward revision of 1.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.

In light of this perspective, let's dive into the average estimates of certain Gilead metrics that are commonly tracked and forecasted by Wall Street analysts.

According to the collective judgment of analysts, 'Product Sales- HIV- Odefsey- Total' should come in at $202.57 million. The estimate suggests a change of -26.9% year over year.

Analysts expect 'Total product sales- Total' to come in at $7.75 billion. The estimate suggests a change of +5.6% year over year.

Based on the collective assessment of analysts, 'Revenues- Royalty contract and other revenues' should arrive at $62.02 million. The estimate indicates a year-over-year change of -85.4%.

Analysts' assessment points toward 'Product Sales- Liver Disease- Vemlidy- Total' reaching $252.48 million. The estimate points to a change of -9.8% from the year-ago quarter.

The average prediction of analysts places 'Product Sales- HIV- Genvoya- U.S.' at $249.96 million. The estimate suggests a change of -22.6% year over year.

It is projected by analysts that the 'Total product sales- U.S.' will reach $5.74 billion. The estimate indicates a change of +8.9% from the prior-year quarter.

The consensus estimate for 'Product Sales- HIV- Odefsey- U.S.' stands at $162.41 million. The estimate indicates a change of -21.2% from the prior-year quarter.

The consensus among analysts is that 'Product Sales- Liver Disease- Vemlidy- U.S.' will reach $118.92 million. The estimate indicates a change of -12.6% from the prior-year quarter.

Analysts predict that the 'Product Sales- Oncology- Cell Therapy- Yescarta- U.S.' will reach $103.23 million. The estimate suggests a change of -16.1% year over year.

The combined assessment of analysts suggests that 'Product Sales- HIV- Biktarvy- U.S.' will likely reach $3.12 billion. The estimate points to a change of +6.3% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Product Sales- HIV- Symtuza-Revenue share- U.S.' of $97.34 million. The estimate indicates a year-over-year change of +2.5%.

Analysts forecast 'Product Sales- Veklury- U.S.' to reach $34.23 million. The estimate suggests a change of -75.6% year over year.

View all Key Company Metrics for Gilead here>>>

Over the past month, Gilead shares have recorded returns of +3.4% versus the Zacks S&P 500 composite's -1.2% change. Based on its Zacks Rank #3 (Hold), GILD will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research